Product logins

Find logins to all Clarivate products below.


Biosimilars – Geographic Focus: China – Biosimilars – China In-Depth (China)

China’s biosimilar market has evolved rapidly over the past four years since the approval of Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab)—in February 2019. As of 2022, there are eight approved biosimilars of Roche’s Avastin (bevacizumab), six of AbbVie’s Humira (adalimumab), and three of J&J’s Remicade (infliximab), with many more in development. China has a high disease burden of cancer and immunological diseases, and the country bears the highest global footprint of many such illnesses. The approval of cost-effective biosimilars has boosted the uptake of biologics in the respective markets. Various regulatory policies are being implemented to streamline the overall drug development, approval, and reimbursement processes, further encouraging adoption of biosimilars in China market.

QUESTIONS ANSWERED

  • Which are the key biologics going off-patent during the 2022-2032 forecast period?
  • How will market dynamics be impacted by the launch of biosimilars for corresponding brands?
  • What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
  • What are the key market access considerations, and how are they likely to impact the uptake of emerging biosimilars in China?

PRODUCT DESCRIPTION

China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

RELEASE DATE

December 2023

GEOGRAPHY

China

PRIMARY RESEARCH

Country-specific qualitative and quantitative insights driven by nine thought-leader experts with extensive experience in pricing, reimbursement, health economics, and pharmaceutical management in China and surveys with 75 medical oncologists and immunologists / rheumatologists

FORECAST

10-year, annualized sales and patient share of key biosimilars in oncology and immunology through 2032, based on primary and secondary market research to formulate bottom-up assumptions.

EMERGING THERAPIES

Phase III/PR: 20+ biosimilars.

Related Market Assessment Reports

Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Report
Biosimilars – Forecast – Respiratory
In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…